Opexa Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1986-01-01
- Employees
- 11
- Market Cap
- -
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
- Conditions
- Autoimmune Diseases of the Nervous SystemMultiple SclerosisSecondary Progressive Multiple SclerosisDisease ProgressionBrain Atrophy
- Interventions
- Biological: PlaceboBiological: Tcelna
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT01684761
- Locations
- 🇺🇸
The Maxine Mesinger MS Clinic/Baylor College of Medicine, Houston, Texas, United States
🇺🇸Alta Bates Summit Medical Center, The Research and Education Development Institute, Berkeley, California, United States
🇺🇸University of Miami, Miami, Florida, United States
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
- Conditions
- Clinically Isolated SyndromeMultiple Sclerosis, Relapsing-Remitting
- Interventions
- Biological: Tovaxin
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT00595920
- Locations
- 🇺🇸
North Central Neurology Associates, PC, Cullman, Alabama, United States
🇺🇸Bradenton Neurology, Bradenton, Florida, United States
🇺🇸Raleigh Neurology Associates, Raleigh, North Carolina, United States
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Relapsing-Remitting
- Interventions
- Biological: Tovaxin Autologous T Cell Vaccine
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00587691
- Locations
- 🇺🇸
Bellaire Neurology, Bellaire, Texas, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Biological: PlaceboBiological: Tovaxin Autologous T cell vaccine
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00245622
- Locations
- 🇺🇸
Neurological Research Institute, Columbus, Ohio, United States
🇺🇸Shepherd Center, Atlanta, Georgia, United States
🇺🇸St Mary's of Michigan - Field Neuroscience Institute, Saginaw, Michigan, United States